Qube Research & Technologies LTD Relmada Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.93 - $4.94 $213,664 - $360,239	-72,923 Reduced 99.92%	56 $0
Q1 2024 May 14, 2024	BUY	$3.1 - $6.8 $210,815 - $462,434	68,005 Added 1367.21%	72,979 $339,000
Q4 2023 Feb 13, 2024	BUY	$2.45 - $4.22 $2,783 - $4,793	1,136 Added 29.6%	4,974 $20,000
Q3 2023 Nov 13, 2023	SELL	$2.48 - $3.79 $103,393 - $158,008	-41,691 Reduced 91.57%	3,838 $11,000
Q2 2023 Aug 14, 2023	BUY	$2.22 - $3.54 $101,074 - $161,172	45,529 New	45,529 $112,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.